Lowest Price Guaranteed From USD 2,499
Published
October 2017
Pages
556
View Count
5905
Example Insights
An updated edition is available at the following link
Report Description
Since the first approval of MYLOTARG™ in 2000 and its subsequent withdrawal in the year 2010, the ADC market has evolved considerably. In the last seven years, the market has witnessed an increasing interest from drug developers and healthcare investors alike. Post the commercialization of ADCETRIS® in 2011 and KADCYLA® in 2013, there was a temporary, but evident, decline in the popularity of ADCs. This was attributed to the fact that no new ADC candidates were approved after 2013 and the focus had shifted to other novel therapies, such as immune checkpoint inhibitors and T-cell therapies. However, the recent approval of BESPONSA® and re-approval of MYLOTARG™ has renewed the interest of stakeholders in the domain. This growing popularity and potential of ADCs can also be correlated with an exponential increase in the number of patents that have been filed; the cumulative number has increased from 1,395 patents in 2009 to 10,208 patents in the first half of 2017.
While there are close to 200 ADCs in clinical / preclinical stages of development, the field is currently going through a gradual transition. The industry is shifting from relying on conventional technologies to newer approaches for generating ADCs. This transition has paved way for several well-funded start-ups, which offer novel conjugation approaches, more potent warheads and modified linker technologies. In addition, the ADCs are now being evaluated in combination with several other novel therapies, such as immune checkpoint inhibitors, epigenetic modulators and monoclonal antibodies.
Scope of the Report
The ‘Antibody Drug Conjugates Market (4th Edition), 2017-2030’ report provides a comprehensive study on the current landscape of ADCs, featuring an elaborate discussion on the future potential of this evolving market. The field has captured the interest of several drug developers, both small and large companies. While more than half of these pipeline candidates are in the discovery / preclinical stages, around 10% of candidate therapies are presently in advanced stages (phase II and above); we anticipate the market to witness continued growth in the next 5-10 years. Amongst other elements, the report features:
One of the key objectives of the report was to understand the primary growth drivers and estimate the future size of the market. Based on parameters, such as target consumer segments, likely adoption rates and expected pricing, we have provided an informed estimate on the likely evolution of the market in the short to mid-term and long term, for the period 2017-2030. The research, analysis and insights presented in this report include potential sales of ADCs that are currently marketed or are in the late stages of development. To account for the uncertainties associated with the development of novel ADCs and to add robustness to our model, we have provided three forecast scenarios, portraying the conservative, base and optimistic tracks of the market’s evolution.
The opinions and insights presented in the report were influenced by discussions with senior stakeholders in the industry. These include Alan Burnett (Professor, School of Medicine, James Cardiff University), Aldo Braca, (Chief Executive Officer, BSP Pharmaceuticals), Anthony DeBoer (Director, Business Development, Synaffix), Anonymous (Chief Executive Officer, Leading CMO), Christian Bailly (Head of CDMO, Pierre Fabre), Christian Rohlff, (Founder and CEO, Oxford BioTherapeutics), Anonymous (Director, Business Development, Leading CMO), John Burt (Chief Executive Officer, Abzena), Laurent Ducry (ADC R&D, Lonza), Mark Wright (Site Head, Grangemouth, Piramal Healthcare), Sasha Koniev (Chief Executive Officer, Syndivia), Stacy McDonald (Group Product Manager) and Jennifer L. Mitcham (Director, Business Development, Catalent Pharma Solutions). All actual figures have been sourced and analyzed from publicly available information forums and primary research discussions. Financial figures mentioned in this report are in USD, unless otherwise specified.
Contents
Chapter 2 provides an executive summary of the insights captured in our research. It offers a high-level view on the likely evolution of the ADCs market in the short-mid and long term.
Chapter 3 provides a general introduction to ADCs. In this section, we have discussed, in detail, the concept of ADC, its components, mechanisms of action and advantages over traditional targeted therapies. The chapter also presents a brief description of the Absorption, Distribution, Metabolism and Excretion (ADME) properties of the various ADCs in development.
Chapter 4 provides a comprehensive overview of the market landscape of ADCs under development (clinical and preclinical). This chapter includes information related to these candidates, along with their current phase of development, key target indications, developer companies and the most common types of cytotoxins and linkers used. The chapter also highlights the various ADCs that have been discontinued over the last few years.
Chapter 5 provides an extensive list of the key opinion leaders (KOLs) in the field of ADCs. It contains schematic representations of world maps highlighting the geographical locations of these eminent scientists / researchers. The chapter presents a detailed 2X2 analysis to assess the relative experience of certain KOLs based on the number of clinical studies they participated in and the highest phase of development they investigated.
Chapter 6 identifies the most commonly targeted therapeutic indications and features brief discussions on the ADCs being developed against them. It highlights the key epidemiological facts of the various disorders and lists the currently available treatment options.
Chapter 7 presents elaborate profiles of clinical stage companies and drugs; each profile features an overview of the company, its financial performance and product portfolio, including detailed information on advanced stage pipeline candidates (featuring a drug overview, mechanism of action, information on clinical trials and key clinical trial results).
Chapter 8 features an elaborate discussion and analysis of the various collaborations and partnerships that have been inked amongst players in this market. We have also highlighted the key players, the different partnership models (such as R&D agreements, technology / product licensing, product development and commercialization agreements, mergers / acquisitions, and clinical trial collaborations) and the most common forms of deals / agreements that have been established in this domain.
Chapter 9 presents details on various investments received by companies that are focused on development of ADCs. It also includes an analysis of the funding instances that have taken place in last ten years, highlighting the growing interest of the venture capital community and other strategic investors in this market.
Chapter 10 provides a detailed analysis of the academic grants that have been awarded in this field. In addition to highlighting various key funding institutes, the chapter provides various indications and molecular targets across which, majority of the research work is currently focused.
Chapter 11 features an overview of the various therapies being evaluated in combination with ADCs. It also features a study of the likely evolution of these therapies across different therapeutic indications.
Chapter 12 features an elaborate discussion and competitive analysis of the various ADC conjugation approaches. This chapter also features an overview of the evolution of these technologies in addition to highlighting the competition between contemporary technology platforms.
Chapter 13 provides an overview of the studies conducted to better analyze non-clinical data and support first-in-human (FIH) dose selection. The chapter presents insights from recently conducted studies in different animal models, analyzing the different methods used in estimating FIH doses. In addition, it presents possible FIH starting doses and the estimated dose escalations required to reach human maximum tolerated dose (MTD). The chapter highlights different types of ADC related toxicities observed in animal models, highlighting the doses at which these toxicities were observed.
Chapter 14 provides a detailed analysis of the patents that have been filed in the ADCs space. The study highlights emerging trends in the patents that have been filed and identifies the key players that are driving the innovation in this area. It also presents a high-level view on the valuation of these patents.
Chapter 15 provides details on the various players that offer contract manufacturing services for ADCs, or possess the necessary capabilities and infrastructure to manufacture such products in-house. The chapter illustrates the manufacturing capabilities of different contract manufacturers highlighting the various recent expansion plans and other agreements inked between companies.
Chapter 16 presents a comprehensive market forecast analysis, highlighting the future potential of the market till the year 2030. It includes future sales projections of ADCs that are either marketed or are in advanced stages of clinical development (phase II and preregistration). The sales potential and growth opportunity were estimated based on the target patient population, likely adoption rates, existing / future competition from other drug classes and the likely price of products. The chapter also presents a detailed market segmentation on the basis of key indications, payloads and linkers.
Chapter 17 provides a detailed analysis capturing the key parameters and trends that are likely to influence the future of the ADCs market within the biopharmaceutical industry, under a comprehensive SWOT framework.
Chapter 18 summarizes the overall report. The chapter provides a list of the key takeaways and presents our independent opinion on the ADC market, based on the research and analysis described in the previous chapters.
Chapter 19 is a collection of interview transcripts of the discussions held with key stakeholders in this market. In this chapter, we have presented the details of our conversations with Alan Burnett (Professor, School of Medicine, James Cardiff University), Aldo Braca, (Chief Executive Officer, BSP Pharmaceuticals), Anthony DeBoer (Director, Business Development, Synaffix), Anonymous (Chief Executive Officer, Leading CMO), Christian Bailly (Head of CDMO, Pierre Fabre), Christian Rohlff, (Founder and CEO, Oxford BioTherapeutics), Anonymous (Director, Business Development, Leading CMO), John Burt (Chief Executive Officer, Abzena), Laurent Ducry (ADC R&D, Lonza), Mark Wright (Site Head, Grangemouth, Piramal Healthcare), Sasha Koniev (Chief Executive Officer, Syndivia), Stacy McDonald (Group Product Manager) and Jennifer L. Mitcham (Director, Business Development, Catalent Pharma Solutions).
Chapter 20 is an appendix, which provides tabulated data and numbers for all the figures provided in the report.
Chapter 21 is an appendix, which provides the list of companies and organizations mentioned in the report.
1. PREFACE
1.1. Scope of the Report
1.2. Research Methodology
1.3. Chapter Outlines
2. EXECUTIVE SUMMARY
3. INTRODUCTION
3.1. Chapter Overview
3.2. Evolution of Cancer Treatment
3.3. Cancer Treatment Methods
3.3.1. Surgery
3.3.2. Radiation Therapy
3.3.3. Chemotherapy
3.3.4. Targeted Therapies
3.4. Monoclonal Antibodies to Treat Cancer
3.5. Essential Components of Antibody Drug Conjugates (ADCs)
3.5.1. Antibody
3.5.2. Cytotoxin
3.5.3. Linker
3.6. Advantages of ADCs over Traditional Therapeutics
3.7. ADCs, Monoclonal Antibodies and Small Molecule Drugs: Comparison of Key Properties
3.8. ADME Properties of ADCs
3.8.1. Absorption
3.8.2. Distribution
3.8.3. Metabolism and Elimination
4. MARKET OVERVIEW
4.1. Chapter Overview
4.2. ADCs: Clinical Pipeline
4.2.1. ADCs Clinical Pipeline: Distribution by Phase of Development
4.2.2. ADCs Clinical Pipeline: Distribution by Indication
4.2.3. ADCs Clinical Pipeline: Distribution by Target
4.2.4. ADCs Clinical Pipeline: Distribution by Type of Linker
4.2.5. ADCs Clinical Pipeline: Distribution by Type of Warhead
4.2.6. ADCs Clinical Pipeline: Distribution by Technology Providers
4.2.7. ADCs Clinical Pipeline: Distribution by Targets and Indication
4.2.8. ADCs Clinical Pipeline: Four-Dimensional Grid Analysis
4.2.9. ADCs Clinical Pipeline: Discontinued Drugs
4.3. ADCs: Preclinical Pipeline
4.3.1. ADCs Preclinical Pipeline: Distribution by Key Players
5. KEY OPINION LEADERS
5.1. Chapter Overview
5.2. Current Research Landscape
5.2.1. ADCETIRS®: Key Opinion Leaders
5.2.2. KADCYLA®: Key Opinion Leaders
5.2.3. MYLOTARG™: Key Opinion Leaders
5.2.4. Other ADCs: Key Opinion Leaders
5.3. Most Prominent Key Opinion Leaders
6. KEY THERAPEUTIC AREAS
6.1. Chapter Overview
6.2. Hematological Malignancies
6.2.1. Leukemias and Lymphomas
6.2.1.1. Leukemia: Introduction and Epidemiology
6.2.1.1.1. Acute Myeloid Leukemia
6.2.1.1.2. Chronic Myeloid Leukemia
6.2.1.1.3. Acute Lymphocytic Leukemia
6.2.1.1.4. Chronic Lymphocytic Leukemia
6.2.1.2. Lymphoma: Introduction and Epidemiology
6.2.1.3. Current Treatment Landscape
6.2.1.4. ADCs for Leukemia / Lymphoma
6.2.2. Multiple Myeloma
6.2.2.1. Introduction and Epidemiology
6.2.2.2. Current Treatment Landscape
6.2.2.3. ADCs for Multiple Myeloma
6.3. Solid Tumors
6.3.1. Metastatic Melanoma
6.3.1.1. Introduction and Epidemiology
6.3.1.2. Current Treatment Landscape
6.3.1.3. ADCs for Metastatic Melanoma
6.3.2. Lung Cancer
6.3.2.1. Introduction and Epidemiology
6.3.2.2. Current Treatment Landscape
6.3.2.3. ADCs for Lung Cancer
6.3.3. Bladder Cancer
6.3.3.1. Introduction and Epidemiology
6.3.3.2. Current Treatment Landscape
6.3.3.3. ADCs for Bladder Cancer
6.3.4. Kidney Cancer
6.3.4.1. Introduction and Epidemiology
6.3.4.2. Current Treatment Landscape
6.3.4.3. ADCs for Kidney Cancer
6.3.5. Ovarian Cancer
6.3.5.1. Introduction and Epidemiology
6.3.5.2. Current Treatment Landscape
6.3.5.3. ADCs for Ovarian Cancer
6.3.6. Breast Cancer
6.3.6.1. Introduction and Epidemiology
6.3.6.2. Current Treatment Landscape
6.3.6.3. ADCs for Breast Cancer
6.3.7. Glioblastoma
6.3.7.1. Introduction and Epidemiology
6.3.7.2. Current Treatment Landscape
6.3.7.3. ADCs for Glioblastoma
6.3.8. Colorectal Cancer
6.3.8.1. Introduction and Epidemiology
6.3.8.2. Current Treatment Landscape
6.3.8.3. ADCs for Colorectal Cancer
6.3.9. Prostate Cancer
6.3.9.1. Introduction and Epidemiology
6.3.9.2. Current Treatment Landscape
6.3.9.3. ADCs for Prostate Cancer
7. COMPANY AND DRUG PROFILES
7.1. Chapter Overview
7.2. AbbVie
7.2.1. Company Overview
7.2.2. Financial Performance
7.2.3. Pipeline Overview
7.2.3.1. ABT-414
7.2.3.1.1 Drug Overview
7.2.3.1.2. Mechanism of Action
7.2.3.1.3. Clinical Development Status
7.2.3.1.4. Key Clinical Trial Results
7.2.4. Recent Collaborations
7.3. Astellas Pharma
7.3.1. Company Overview
7.3.2. Financial Performance
7.3.3. Pipeline Overview
7.3.3.1. ASG-22ME
7.3.3.1.1. Drug Overview
7.3.3.1.2. Mechanism of Action
7.3.3.1.3. Clinical Development Status
7.3.3.1.4. Key Clinical Trial Results
7.3.3.2. ASG16-M8F
7.3.3.2.1. Drug Overview
7.3.3.2.2. Mechanism of Action
7.3.3.2.3. Clinical Development
7.3.3.2.4. Key Clinical Trial Results
7.3.4. Recent Collaborations
7.4. Bayer HealthCare
7.4.1. Company Overview
7.4.2. Financial Performance
7.4.3. Pipeline Overview
7.4.3.1. BAY 94-9343
7.4.3.1.1. Drug Overview
7.4.3.1.2. Mechanism of Action
7.4.3.1.3. Clinical Development Status
7.4.3.1.4. Key Clinical Results
7.4.4. Recent Collaborations
7.5. Biotest Pharmaceuticals
7.5.1. Company Overview
7.5.2. Financial Performance
7.5.3. Pipeline Overview
7.5.3.1. BT-062
7.5.3.1.1. Drug Overview
7.5.3.1.2. Mechanism of Action
7.5.3.1.3. Clinical Development Status
7.5.3.1.4. Key Clinical Trial Results
7.5.4. Recent Collaborations
7.6. Celldex Therapeutics
7.6.1. Company Overview
7.6.2. Financial Performance
7.6.3. Pipeline Overview
7.6.3.1. CDX-011
7.6.3.1.1. Drug Overview
7.6.3.1.2. Mechanism of Action
7.6.3.1.3. Clinical Development Status
7.6.3.1.4. Key Clinical Trial Results
7.6.4. Recent Collaborations
7.7. ImmunoGen
7.7.1. Company Overview
7.7.2. Financial Performance
7.7.3. Pipeline Overview
7.7.3.1. IMGN853
7.7.3.1.1. Drug Overview
7.7.3.1.2. Mechanism of Action
7.7.3.1.3. Clinical Development Status
7.7.3.1.4. Key Clinical Trial Results
7.7.3.2. IMGN529 / Debio1562
7.7.3.2.1. Drug Overview
7.7.3.2.2. Mechanism of Action
7.7.3.2.3. Clinical Development Status
7.7.3.2.4. Key Clinical Results
7.7.3.3. SAR3419
7.7.3.3.1. Drug Overview
7.7.3.3.2. Mechanism of Action
7.7.3.3.3. Clinical Development Status
7.7.3.3.4. Key Clinical Trial Results
7.7.4. Collaborations
7.8. Immunomedics
7.8.1. Company Overview
7.8.2. Financial Performance
7.8.3. Pipeline Overview
7.8.3.1. IMMU-130
7.8.3.1.1. Drug Overview
7.8.3.1.2. Mechanism of Action
7.8.3.1.3. Clinical Development Status
7.8.3.1.4. Key Clinical Trial Results
7.8.3.2. IMMU-132
7.8.3.2.1. Drug Overview
7.8.3.2.2. Mechanism of Action
7.8.3.2.3. Clinical Development Status
7.8.3.2.4. Key Clinical Trial Results
7.8.4. Recent Collaborations
7.9. Progenics Pharmaceuticals
7.9.1. Company Overview
7.9.2. Financial Performance
7.9.3. Pipeline Overview
7.9.3.1. PSMA ADC
7.9.3.1.1. Drug Overview
7.9.3.1.2. Mechanism of Action
7.9.3.1.3. Clinical Development Status
7.9.3.1.4. Key Clinical Trial Results
7.9.4. Recent Collaborations
7.10. Pfizer
7.10.1. Company Overview
7.10.2. Financial Performance
7.10.3. Pipeline Overview
7.10.3.1. BESPONSA®
7.10.3.1.1. Drug Overview
7.10.3.1.2. Mechanism of Action
7.10.3.1.3. Approval History
7.10.3.1.4. Clinical Development Status
7.10.3.1.5. Key Clinical Trial Results
7.10.3.2. MYLOTARG™
7.10.3.2.1. Drug Overview
7.10.3.2.2. Mechanism of Action
7.10.3.2.3. Approval History
7.10.3.2.4. Clinical Development Status
7.10.3.2.5. Key Clinical Trial Results
7.10.4. Recent Collaborations
7.11. Roche / Genentech
7.11.1. Company Overview
7.11.2. Financial Performance:
7.11.3. Pipeline Overview
7.11.3.1. KADCYLA®
7.11.3.1.1. Drug Overview
7.11.3.1.2. Mechanism of Action
7.11.3.1.3. Cost, Dosage and Reimbursement
7.11.3.1.4. Approval History
7.11.3.1.5. KADCYLA Sales, 2013-Q1 2017
7.11.3.1.6. Clinical Development Status
7.11.3.1.7. Key Clinical Trial Results
7.11.3.2. RG-7596
7.11.3.2.1. Drug Overview
7.11.3.2.2. Mechanism of Action
7.11.3.2.3. Clinical Development
7.11.3.2.4. Key Clinical Trial Results
7.11.4. Recent Collaborations
7.12. Sanofi
7.12.1. Company Overview
7.12.2. Financial Performance-
7.12.3. Pipeline Overview
7.12.3.1. SAR-566658 / huDS6-DM4
7.12.3.1.1. Drug Overview
7.12.3.1.2. Mechanism of Action
7.12.3.1.3. Clinical Development
7.12.3.1.4. Key Clinical Results
7.12.4. Recent Collaborations
7.13. Seattle Genetics
7.13.1. Company Overview
7.13.2. Financial Performance
7.13.3. Pipeline Overview
7.13.3.1. ADCETRIS®
7.13.3.1.1. Drug Overview
7.13.4. Mechanism of Action
7.13.4.1.1. Cost, Dosage and Reimbursement
7.13.4.1.2. Approval History
7.13.4.1.3. ADCETRIS® Sales, 2011-H1 2017
7.13.4.1.4. Clinical Development
7.13.4.1.5. Key Clinical Trial Results
7.13.4.2. SGN-CD19A
7.13.4.2.1. Drug Overview
7.13.4.2.2. Mechanism of Action
7.13.4.2.3. Clinical Development
7.13.4.2.4. Key Clinical Trial Results
7.13.5. Recent Collaborations
8. PARTNERSHIPS AND COLLABORATIONS
8.1. Chapter Overview
8.2. Partnership Models
8.3. ADCs: List of Partnerships
8.4. ADCs: Analysis of Partnerships
8.4.1 Analysis by Year of Partnerships
8.4.2. Analysis by Type of Partnerships
8.4.3. Most Active Companies: Analysis by Number of Partnerships
9. VENTURE FUNDING
9.1. Chapter Overview
9.2. Types of Funding
9.3. ADCs: Funding Instances
9.4. ADCs: Analysis of Funding
9.4.1. Analysis by Number of Funding Instances
9.4.2. Analysis by Amount Invested
9.4.3. Analysis by Type of Funding
9.4.4. Most Active Companies: Analysis by Number of Funding Instances
9.4.5. Most Active Investors: Analysis by Number of Funding Instances
10. ACADEMIC GRANTS
10.1. Chapter Overview
10.2. ADCs: List of Recent Academic Grants
10.3. ADCs: Analysis of Grants
10.3.1. Analysis by Number of Grants
10.3.2. Analysis by Amount of Grant
10.3.3. Analysis by Type of Grant
10.3.4. Analysis by Leading Organization
10.3.5. Analysis by Therapeutic Area
10.3.6. Analysis by Therapeutic Target
11. COMBINATION THERAPIES
11.1. Chapter Overview
11.2. Combination Therapy: History of Development
11.3. FDA-approved Combination Therapies in Oncology
11.4. Combination Therapies: FDA Guidelines
11.4.1. Combinations of Marketed Drugs
11.4.2. Combinations of Marketed Drugs or Biologics with New Molecular Entities
11.4.3. Combinations of New Molecular Entities
11.5. Combination Therapies: ADCs
11.5.1. ADCs Clinical Studies: Distribution by Therapy Type
11.5.2. ADCs Combination Therapy Clinical Studies
11.5.3. ADCs: Analysis of Combinations
11.5.2.1. Analysis by Highest Phase of Development
11.5.2.2. Analysis by Current Trial Status
11.5.2.3. Analysis by Type of Combination Therapy
11.5.2.4. Analysis by Indication and Combination
12. NOVEL CONJUGATION TECHNOLOGY PLATFORMS
12.1. Chapter Overview
12.2. First Generation ADC Technologies
12.3. Second Generation ADC Technologies
12.3.1. Cysteine and Selenocysteine Engineering
12.3.2. Unnatural Amino Acid Engineering
12.3.3. Amino-Terminal Engineered Serine
12.4. Third Generation ADC Technologies
12.4.1. Enzyme-Assisted Ligation Approaches
12.4.2. Glycan Remodeling Approaches
12.4.3. Ligation at Fab Nucleotide-Binding Site
12.4.4. Cysteine Rebridging
12.4.5. Avoiding or Limiting Retro-Michael Drug Deconjugation
12.5. Evolutionary Analysis
13. ASSESMENT OF NON-CLINICAL DATA, FIRST IN HUMAN DOSING
13.1. Chapter Overview
13.2. ADCs and Non-Clinical Studies
13.3. ICH S9 Guidelines
13.4. Investigational New Drug (IND)-Enabling Study Designs
13.4.1. Example Case: KADCYLA®
13.5. Toxicities in Animal Models
13.6. Prediction of Maximum Tolerated Dosage (MTD) in Humans
13.7. Other Key Considerations for Study Design
14. PATENT ANALYSIS
14.1. Chapter Overview
14.2. Scope and Methodology
14.3. ADC Patents: Distribution by Publication Year
14.4. ADC Patents: Distribution by Geographical Location
14.5. ADC Patents: Distribution by CPC Classifications
14.6. ADC Patents: Emerging Areas
14.7. ADC Patents: Leading Players
14.8. ADC Patents: Benchmarking Analysis
14.8.1. Benchmarking Analysis: Patent Characteristics
14.8.2. Benchmarking Analysis: Geographical Distribution
14.9. ADC Patents: Emerging Players
14.10. ADC Patents: Patent Valuation
14.11. ADC Patents: Leading Citations
15. CASE STUDY: ADC MANUFACTURING
15.1. Chapter Overview
15.2. Key Steps in ADC Manufacturing
15.3. Challenges Associated with ADC Manufacturing
15.4. Limitations of In-House Manufacturing
15.5. Growing Demand for Contract Manufacturing
15.6. Emergence of Start-Ups Offering Contract Services
15.7. Investments in ADC Manufacturing Capability Expansions
15.8. Collaborations Established for ADC Manufacturing
15.9. CMOs with Linker Manufacturing Capabilities
15.10. CMOs with HPAPI / Cytotoxic Payload Manufacturing Capabilities
15.11. CMOs with Conjugation Capabilities
15.12. ADC One Stop Shops
16. MARKET FORECAST AND OPPORTUNITY ANALYSIS
16.1. Chapter Overview
16.2. Scope and Limitations
16.3. Forecast Methodology
16.4. Overall ADCs Therapeutics Market
16.4.1. ADCs Therapeutics Market: Distribution by Therapeutic Area
16.4.2. ADCs Therapeutics Market: Distribution by Technology Providers
16.4.3. ADCs Therapeutics Market: Distribution by Type of Linker
16.4.4. ADCs Therapeutics Market: Distribution by Type of Payload
16.5. ADCs Therapeutics Market: Individual Drug Forecasts
16.5.1. ADCETRIS®
16.5.1.1. Target Patient Population
16.5.1.2. Sales Forecast
16.5.2. KADCYLA®
16.5.2.1. Target Patient Population
16.5.2.2. Sales Forecast
16.5.3. MYLOTARG™
16.5.3.1. Target Patient Population
16.5.3.2. Sales Forecast
16.5.4. BESPONSA®
16.5.4.1. Target Patient Population
16.5.4.2. Sales Forecast
16.5.5. IMMU-132
16.5.5.1. Target Patient Population
16.5.5.2. Sales Forecast
16.5.6. Rova-T
16.5.6.1. Target Patient Population
16.5.6.2. Sales Forecast
16.5.7. IMGN853
16.5.7.1. Target Patient Population
16.5.7.2. Sales Forecast
16.5.8. RG7596
16.5.8.1. Target Patient Population
16.5.8.2. Sales Forecast
16.5.9. PSMA ADC
16.5.9.1. Target Patient Population
16.5.9.2. Sales Forecast
16.5.10. BAY 94-9343
16.5.10.1. Target Patient Population
16.5.10.2. Sales Forecast
16.5.11. SAR3419
16.5.11.1. Target Patient Population
16.5.11.2. Sales Forecast
16.5.12. IMMU-130
16.5.12.1. Target Patient Population
16.5.12.2. Sales Forecast
16.5.13. AGS 16M8F / AGS 16C3F
16.5.13.1. Target Patient Population
16.5.13.2. Sales Forecast
16.5.14. CDX-011
16.5.14.1. Target Patient Population
16.5.14.2. Sales Forecast
16.5.15. SAR566658
16.5.15.1. Target Patient Population
16.5.15.2. Sales Forecast
16.5.16. ABT-414
16.5.16.1. Target Patient Population
16.5.16.2. Sales Forecast
16.5.17. SGN-CD19A
16.5.17.1. Target Patient Population
16.5.17.2. Sales Forecast
16.5.18. IMGN529
16.5.18.1. Target Patient Population
16.5.18.2. Sales Forecast
16.5.19. ASG-22ME
16.5.19.1. Target Patient Population
16.5.19.2. Sales Forecast
17. SWOT ANALYSIS
17.1. Chapter Overview
17.2. Strengths
17.3. Weaknesses
17.4. Opportunities
17.5. Threats
18. CONCLUSION
18.1. The Recent Approval of MYLOTARG™ and BESPONSA® has Renewed the Interest in ADCs
18.2. In Addition to Established Players, Start-ups, Backed by Venture Capital Investors, are Significantly Driving Innovation in this Domain
18.3. With Multiple Late-phase Candidates, the ADCs Space is Characterized by a Robust and Promising Pipeline
18.4. More Potent Warheads, Novel Targets and Innovative Conjugation Platforms have Emerged as Potential Areas of Research
18.5. Several Stakeholders have Entered into Strategic Alliances to Further R&D Efforts in this Domain
18.6. CMOs Continue to a Play Significant Role in Driving the Industry Forward
18.7. Post the Approval and Launch of Multiple Late-phase Product Candidates, the Market is Expected to Grow at a Rapid Pace
19. INTERVIEW TRANSCRIPTS
19.1. Chapter Overview
19.2. Alan Burnett, Professor, School of Medicine, James Cardiff University
19.3. Sasha Koniev, Chief Executive Officer, Syndivia
19.4. Anthony DeBoer, Director, Business Development, Synaffix
19.4. Mark Wright, Site Head, Grangemouth, Piramal Healthcare
19.6. Christian Bailly, Head of CDMO, Pierre Fabre
19.7. Anonymous, Director, Business Development, Leading CMO
19.8. John Burt, Chief Executive Officer, Abzena
19.9. Christian Rohlff, Founder and CEO, Oxford BioTherapeutics
19.10. Laurent Ducry, ADC R&D, Lonza
19.11. Stacy McDonald, Group Product Manager and Jennifer L. Mitcham, Director, Business Development, Catalent Pharma Solutions
19.12. Aldo Braca, Chief Executive Officer, BSP Pharmaceuticals
19.13. Anonymous, Chief Executive Officer, Leading CMO
20. APPENDIX 1: TABULATED DATA
21. APPENDIX 2: LIST OF COMPANIES AND ORGANIZATIONS
Figure 3.1 Cancer Treatments: Timeline
Figure 3.2 Cancer Treatments: Type of Surgeries
Figure 3.3 Cancer Treatments: Type of Radiation Therapies
Figure 3.3 Cancer Treatments: Type of Chemotherapies
Figure 3.4 Components of ADC
Figure 3.5 Comparative Analysis of Pharmacokinetic Properties of ADCs: Dosage, Regimen, Cmax and T1/2
Figure 4.1 ADCs Clinical Pipeline: Distribution by Phase of Development
Figure 4.2 ADCs Clinical Pipeline: Distribution by Indication
Figure 4.3 ADCs Clinical Pipeline: Distribution by Target
Figure 4.4 ADCs Clinical Pipeline: Distribution by Type of Linker
Figure 4.5 ADCs Clinical Pipeline: Distribution by Type of Warhead
Figure 4.6 ADCs Clinical Pipeline: Distribution by Technology Providers
Figure 4.7 ADCs Clinical Pipeline: Four-Dimensional Grid Analysis
Figure 4.8 ADCs Preclinical Pipeline: Distribution by Key Players
Figure 5.1 ADCETRIS®: Mapping Prominent Researchers
Figure 5.2 KADCYLA®: Mapping Prominent Researchers
Figure 5.3 MYLOTARG™: Mapping Prominent Researchers
Figure 5.4 Other ADCs: Mapping Prominent Researchers
Figure 5.5 ADCs: Prominent Key Opinion Leaders
Figure 6.1 Leukemia: Classification
Figure 6.2 Leukemia: Global Epidemiological Distribution
Figure 6.3 Lymphoma: Global Epidemiological Distribution
Figure 6.4 Multiple Myeloma: Global Epidemiological Distribution
Figure 6.5 Melanoma: Global Epidemiological Distribution
Figure 6.6 Lung Cancer: Classification
Figure 6.7 Lung Cancer: Global Epidemiological Distribution
Figure 6.8 Bladder Cancer: Global Epidemiological Distribution
Figure 6.9 Kidney Cancer: Global Epidemiological Distribution
Figure 6.10 Ovarian Cancer: Global Epidemiological Distribution
Figure 6.11 Breast Cancer: Global Epidemiological Distribution
Figure 6.12 Colorectal Cancer: Global Epidemiological Distribution
Figure 6.13 Prostate Cancer: Global Epidemiological Distribution
Figure 7.1 AbbVie: Annual Revenues, 2012-H1 2017 (USD Billion)
Figure 7.2 ABT-414: Registered Clinical Trials
Figure 7.3 Astellas Pharma: Annual Revenues, 2012-2017 (JPY Billion)
Figure 7.4 ASG-22ME: Registered Clinical Trials, 2017
Figure 7.5 ASG-22ME: Key Clinical Trial Results, June 2017
Figure 7.6 ASG 16M8F: Registered Clinical Trials, 2017
Figure 7.7 Bayer Healthcare: Annual Revenues, 2012-H1 2017 (EUR Billion)
Figure 7.8 BAY 94-9343: Registered Clinical Trials
Figure 7.9 Biotest Pharmaceuticals: Annual Revenues, 2012-2016 (EUR Million)
Figure 7.10 BT-062: Registered Clinical Trials
Figure 7.11 Celldex Therapeutics: Annual Revenues, 2012-H1 2017 (USD Million)
Figure 7.12 CDX-011: Registered Clinical Trials
Figure 7.13 ImmunoGen: Annual Revenues, 2012-H1 2017 (USD Million)
Figure 7.14 IMGN853: Registered Clinical Trials
Figure 7.15 IMGN853: Treatment-Related Adverse Events for Solid Tumors
Figure 7.16 IMGN853: Treatment-Related Adverse Events for Platinum Related Diseases
Figure 7.17 IMGN529: Registered Clinical Trials
Figure 7.18 Immunomedics: Annual Revenues, 2013-2017 (USD Million)
Figure 7.19 IMMU-130: Registered Clinical Trials
Figure 7.20 Progenics Pharmaceuticals: Annual Revenues, 2012-H1 2017 (USD Million)
Figure 7.21 PSMA ADC: Registered Clinical Trials
Figure 7.22 Pfizer: Annual Revenues, 2012-H1 2017 (USD Billion)
Figure 7.23 BESPONSA®: Registered Clinical Trials
Figure 7.24 MYLOTARG™: Mechanism of Action
Figure 7.25 Roche: Annual Revenues, 2012-H1 2017 (USD Billion)
Figure 7.26 KADCYLA®: Registered Clinical Trials
Figure 7.27 KADCYLA®: Annual Sales, 2013-Q1 2017 (CHF Million)
Figure 7.28 RG-7596: Registered Clinical Trials
Figure 7.29 Sanofi: Key Therapeutic Focus Areas
Figure 7.30 Sanofi: Annual Revenues, 2012-2016 (USD Billion)
Figure 7.31 SAR-566658: Registered Clinical Trials
Figure 7.32 Seattle Genetics: Annual Revenues, 2012-H1 2017 (EUR Millions)
Figure 7.33 ADCETRIS®: Registered Clinical Trials
Figure 7.34 ADCETRIS®: Annual Sales, 2012-H1 2017 (USD Million)
Figure 7.35 SGN-CD19A: Registered Clinical Trials
Figure 7.36 SGN-CD19A: Key Clinical Trial Results, December 2015
Figure 8.1 ADC Partnerships: Cumulative Year-wise Trend (2007-2017)
Figure 8.2 ADC Partnerships: Distribution by Most Active Players
Figure 8.3 ADC Partnerships: Distribution by Type of Collaboration
Figure 8.4 ADC Partnerships: Distribution by Year and Type of Collaboration
Figure 9.1 ADCs Investments: Cumulative Number of Funding Instances, Pre-2007-2017
Figure 9.2 ADCs Investments: Cumulative Amount Invested, Pre-2007-2017 (USD Million)
Figure 9.3 ADCs Investments: Distribution of Number of Funding Instance by Type, 2007-2017
Figure 9.4 ADCs Investments: Distribution of Funding Amount by Type, 2007-2017 (USD Million)
Figure 9.5 ADCs Investments: Distribution by Type of Funding and Amount Invested (USD Million)
Figure 9.6 ADCs Investments: Distribution by Leading Players
Figure 9.7 ADC Investments: Most Active Investors
Figure 10.1 ADCs Grants: Distribution by Number of Grants (2011-2017)
Figure 10.2 ADCs Grants: Year-wise Distribution by Grant Amount (USD Million)
Figure 10.3 ADCs Grants: Distribution by Grant Type
Figure 10.4 ADCs Grants: Distribution by States in the US
Figure 10.5 ADC Grants: Distribution by Leading Organizations
Figure 10.6 ADCs Grants: Distribution by Therapeutic Area
Figure 10.7 ADC Grants: Distribution by Therapeutic Target
Figure 11.1 ADCs Clinical Studies: Distribution by Type of Therapy Evaluation
Figure 11.2 ADCs Combination Therapy Clinical Studies: Distribution by Highest Phase of Development
Figure 11.3 ADCs Combination Therapy Clinical Studies: Distribution by Trial Status
Figure 11.4 ADCs Combination Therapy Clinical Studies: Distribution by Trial Date and Type of Combination
Figure 11.5 ADCs Combination Therapy Clinical Studies: Distribution by Indications and Type of Combination
Figure 12.1 ADC Platforms: Technological Evolution
Figure 12.2 ADC Conjugation Platforms: Technology Landscape
Figure 13.1 First in Human Dose Calculation: Dose Escalation using BSA Conversion
Figure 13.2 Relationship between DLTs and ADC Warhead
Figure 13.3 Maximum Tolerated Dose (MTD): Relationship between Drug to Antibody Ratio and (Highest Non-Severely Toxic Dose) HNSTD
Figure 14.1 ADC Patents: Distribution by Type of Patent
Figure 14.2 ADC Patents: Distribution by Publication Year
Figure 14.3 ADC Patents: Year-wise Regional Distribution
Figure 14.4 ADC Patents: Cumulative Distribution by CPC Classification Symbol
Figure 14.5 ADC Patents: Emerging Areas
Figure 14.6 ADC Patents: Distribution by Leading Assignees
Figure 14.7 ADC Patents: Geographical Distribution of Leading Players
Figure 14.8 ADC Patents: Benchmarking by Patent Characteristics
Figure 14.9 ADC Patents: Benchmarking by Geographical Distribution
Figure 14.10 ADC Patents: Benchmarking by International Patents
Figure 14.11 ADC Patents: Emerging Players (2013-2017)
Figure 14.12 ADC Patents: Age of Patent
Figure 14.13 ADC Patents: Patent Valuation
Figure 16.1 Overall ADCs Therapeutics Market, 2017-2030: Base Scenario (USD Billion)
Figure 16.2 ADCs Therapeutics Market (USD Billion), 2017, 2025 and 2030 (Base Scenario): Distribution by Therapeutic Area
Figure 16.3 ADC Therapeutics Market (USD Billion), 2017, 2025 and 2030 (Base Scenario): Distribution by Technology Providers
Figure 16.4 ADCs Therapeutics Market (USD Billion), 2017, 2025 and 2030 (Base Scenario): Distribution by Type of Linker
Figure 16.5 ADCs Therapeutics Market (USD Billion), 2017, 2025 and 2030 (Base Scenario): Distribution by Type of Payload
Figure 16.6 ADCETRIS® Sales Forecast (Till 2030): Base Scenario (USD Million)
Figure 16.7 KADCYLA® Sales Forecast (Till 2030): Base Scenario (USD Million)
Figure 16.8 MYLOTARG™ Sales Forecast (Till 2030): Base Scenario (USD Million)
Figure 16.9 BESPONSA® Sales Forecast (Till 2030): Base Scenario (USD Million)
Figure 16.10 IMMU-132 Sales Forecast (Till 2030): Base Scenario (USD Million)
Figure 16.11 Rova-T Sales Forecast (Till 2030): Base Scenario (USD Million)
Figure 16.12 IMGN853 Sales Forecast (Till 2030): Base Scenario (USD Million)
Figure 16.13 RG7596 Sales Forecast (Till 2030): Base Scenario (USD Million)
Figure 16.14 PSMA ADC Sales Forecast (Till 2030): Base Scenario (USD Million)
Figure 16.15 BAY 94-9343 Sales Forecast (Till 2030): Base Scenario (USD Million)
Figure 16.16 SAR3419 Sales Forecast (Till 2030): Base Scenario (USD Million)
Figure 16.17 IMMU-130 Sales Forecast (Till 2030): Base Scenario (USD Million)
Figure 16.18 AGS 16M8F / AGS 16C3F Sales Forecast (Till 2030): Base Scenario (USD Million)
Figure 16.19 CDX-011 Sales Forecast (Till 2030): Base Scenario (USD Million)
Figure 16.20 SAR56668 Sales Forecast (Till 2030): Base Scenario (USD Million)
Figure 16.21 ABT-414 Sales Forecast (Till 2030): Base Scenario (USD Million)
Figure 16.22 SGN-CD19A Sales Forecast (Till 2030): Base Scenario (USD Million)
Figure 16.23 IMGN529 Sales Forecast (Till 2030): Base Scenario (USD Million)
Figure 16.24 ASG-22ME Sales Forecast (Till 2030): Base Scenario (USD Million)
Figure 17.1 ADCs SWOT Analysis: Overview
Figure 17.2 ADCs SWOT Analysis: Strengths
Figure 17.3 ADCs SWOT Analysis: Weaknesses
Figure 17.4 ADCs SWOT Analysis: Opportunities
Figure 17.5 ADCs SWOT Analysis: Threats
Figure 19.1 Overall ADCs Therapeutic Market: Conservative, Base and Optimistic Scenario, 2017, 2025 and 2030 (USD Billion)
Table 3.1 FDA Approved Antibody Based Therapeutics for Cancer
Table 3.2 Commonly Used Cytotoxins for ADC Therapeutics
Table 3.3 Occupational Exposure Limit (OEL): Bands
Table 3.4 Comparison of Pharmacokinetic Properties: ADCs, Small Molecules and Monoclonal Antibodies
Table 4.1 ADCs: Clinical Pipeline
Table 4.2 ADCs: Clinical Pipeline (Linker and Payloads)
Table 4.3 ADCs: Discontinued Drugs
Table 4.4 ADCs: Preclinical Pipeline
Table 5.1 ADCs: List of KOLs
Table 6.1 Comparison of Hodgkin’s and Non-Hodgkin’s Lymphoma
Table 6.2 Leukemia: List of Marketed Targeted Therapeutics
Table 6.3 Lymphoma: List of Marketed Targeted Therapeutics
Table 6.4 ADCs for Leukemia and Lymphoma
Table 6.5 Multiple Myeloma: List of Marketed Targeted Therapeutics
Table 6.6 ADCs for Multiple Myeloma
Table 6.7 Melanoma: List of Marketed Targeted Therapeutics
Table 6.8 ADCs for Metastatic Melanoma
Table 6.9 Lung Cancer: List of Marketed Targeted Therapeutics
Table 6.10 ADCs for Lung Cancer
Table 6.11 ADCs for Bladder Cancer
Table 6.12 Renal Cell Carcinoma: List of Marketed Targeted Therapeutics
Table 6.13 ADCs for Kidney Cancer
Table 6.14 ADCs for Ovarian Cancer
Table 6.15 Breast Cancer: List of Marketed Targeted Therapeutics
Table 6.16 ADCs for Breast Cancer
Table 6.17 ADCs for Glioblastoma
Table 6.18 Colorectal Cancer: List of Marketed Targeted Therapeutics
Table 6.19 ADCs for Colorectal Cancer
Table 6.20 Prostate Cancer: List of Marketed Targeted Therapeutics
Table 6.21 ADCs for Prostate Cancer
Table 7.1 AbbVie: ADCs Pipeline
Table 7.2 ABT-414: Registered Clinical Trials
Table 7.3 Astellas Pharma: ADCs Pipeline
Table 7.4 ASG-22ME: Registered Clinical Trials
Table 7.5 ASG 16M8F: Registered Clinical Trials
Table 7.6 Bayer Healthcare: ADCs Pipeline
Table 7.7 BAY 94-9343: Registered Clinical Trials
Table 7.8 Biotest Pharmaceuticals: ADCs Pipeline
Table 7.9 BT-062: Registered Clinical Trials
Table 7.10 Celldex Therapeutics: ADCs Pipeline
Table 7.11 CDX-011: Registered Clinical Trials
Table 7.12 ImmunoGen: ADCs Pipeline
Table 7.13 IMGN853: Registered Clinical Trials
Table 7.14 IMGN529: Registered Clinical Trials
Table 7.15 Immunomedics: ADCs Pipeline
Table 7.16 IMMU-130: Registered Clinical Trials
Table 7.17 IMMU-130: Registered Clinical Trials
Table 7.18 Progenics Pharmaceuticals: ADCs Pipeline
Table 7.19 PSMA ADC: Registered Clinical Trials
Table 7.20 Pfizer: ADCs Pipeline
Table 7.21 BESPONSA®: Registered Clinical Trials
Table 7.22 MYLOTARG™: Registered Clinical Trials
Table 7.23 Roche: ADCs Pipeline
Table 7.24 KADCYLA®: Ongoing Clinical Trials
Table 7.25 RG-7596: Registered Clinical Trials
Table 7.26 ASG-22ME: Registered Clinical Trials
Table 7.27 Seattle Genetics: ADCs Pipeline
Table 7.28 ADCETRISR®: Registered Clinical Trials
Table 7.29 SGN-CD19A: Registered Clinical Trials
Table 8.1 ADCs: List of Partnerships, 2005-2017
Table 9.1 ADCs: List of Funding Instances, Pre-2007-2017
Table 9.2 ADCs: Types of Funding Instances, Pre- 2007-2017
Table 10.1 ADCs: List of Academic Grants, 2011-2017
Table 11.1 FDA Approved Combination Therapies in Oncology, 2001-2015
Table 11.2 ADCs Combination Therapy Clinical Studies: Key Indications
Table 12.1 Second Generation ADC Technologies: Cysteine and Selenocysteine Engineering
Table 12.2 Second Generation ADC Technologies: Unnatural Amino Acid Engineering
Table 12.3 Second Generation ADC Technologies: Amino-terminal Engineered Serine
Table 12.4 Third Generation ADC Technologies: Enzyme-Assisted Ligation Approaches
Table 12.5 Third Generation ADC Technologies: Glycan Remodeling Approaches
Table 12.6 Third Generation ADC Technologies: Enzyme-Assisted Ligation Approaches
Table 12.7 Third Generation ADC Technologies: Cysteine Rebridging
Table 12.8 Third Generation ADC Technologies: Avoiding or Limiting Retro-Michael Drug Deconjugation
Table 13.1 ADCs Non-Clinical Studies: Safety Packages Required
Table 13.2 Single Dose Study of KADCYLA® in Cynomolgus Monkey
Table 13.3 ADCs: Dose Limiting Toxicities in Clinical Studies
Table 14.1 ADCs Patents: CPC Symbol Definitions
Table 14.2 ADCs Patents: Most Popular CPC Symbols
Table 15.1 Contract Manufacturers and Their Capabilities in ADC Manufacturing
Table 15.2 Contract Manufacturers for ADCs: Distribution by Geography
Table 15.3 Full Service Provider CMOs for ADC Manufacturing: Distribution by Geography
Table 16.1 ADCs Therapeutics: Expected Launch Years
Table 16.2 ADCETRIS®: Target Patient Population
Table 16.3 KADCYLA®: Target Patient Population
Table 16.4 MYLOTARG™: Target Patient Population
Table 16.5 BESPONSA®: Target Patient Population
Table 16.6 IMMU-132: Target Patient Population
Table 16.7 Rova-T: Target Patient Population
Table 16.8 IMGN853: Target Patient Population
Table 16.9 RG7596: Target Patient Population
Table 16.10 PSMA ADC: Target Patient Population
Table 16.11 BAY 94-9343: Target Patient Population
Table 16.12 SAR3419: Target Patient Population
Table 16.13 IMMU-130: Target Patient Population
Table 16.14 AGS 16M8F / AGS 16C3F: Target Patient Population
Table 16.15 CDX-011: Target Patient Population
Table 16.16 SAR566658: Target Patient Population
Table 16.17 ABT-414: Target Patient Population
Table 16.18 SGN-CD19A: Target Patient Population
Table 16.19 IMGN529: Target Patient Population
Table 16.20 ASG-22ME: Target Patient Population
Table 20.1 ADCs Clinical Pipeline: Distribution by Phases of Development
Table 20.2 ADCs Clinical Pipeline: Distribution by Indication
Table 20.3 ADCs Clinical Pipeline: Distribution by Target
Table 20.4 ADCs Clinical Pipeline: Distribution by Types of Linker
Table 20.5 ADCs Clinical Pipeline: Distribution by Types of Warhead
Table 20.6 ADCs Clinical Pipeline: Distribution by Technology Providers
Table 20.7 ADCs Clinical Pipeline: Four-Dimensional Grid Analysis
Table 20.8 ADCs Preclinical Pipeline: Distribution by Key Players
Table 20.9 AbbVie: Revenue, 2012 – H1 2017 (USD Billion)
Table 20.10 ABT-414: Registered Clinical Trials
Table 20.11 Astellas Pharma: Revenue, 2012 –2017 (JPY Billion)
Table 20.12 ASG-22ME: Registered Clinical Trials
Table 20.13 ASG 16M8F: Registered Clinical Trials
Table 20.14 Bayer Healthcare: Revenues, 2012 – H1 2017 (EUR Billion)
Table 20.15 BAY 94-9343: Registered Clinical Trials
Table 20.16 Biotest Pharmaceuticals: Revenue, 2012-2016 (EUR Million)
Table 20.17 BT-062: Registered Clinical Trials
Table 20.18 Celldex Therapeutics: Revenue, 2012 – H1 2017 (USD Million)
Table 20.19 CDX-011: Registered Clinical Trials
Table 20.20 ImmunoGen: Revenues, 2012 – H1 2017 (USD Million)
Table 20.21 IMGN853: Registered Clinical Trials
Table 20.22 IMGN529: Registered Clinical Trials
Table 20.23 SAR3419: Registered Clinical Trials
Table 20.24 Immunomedics: Revenues 2013-2017 (USD Million)
Table 20.25 IMMU-130: Registered Clinical Trials
Table 20.26 IMMU-132: Registered Clinical Trials
Table 20.27 Progenics Pharmaceuticals: Revenue, 2012 – H1 2017 (USD Million)
Table 20.28 PSMA ADC: Registered Clinical Trials
Table 20.29 Pfizer: Revenues, 2012 – H1 2017 (USD Billion)
Table 20.30 BESPONSA®: Registered Clinical Trials
Table 20.31 MYLOTARG™: Registered clinical trials, 2017
Table 20.32 Roche: Revenues, 2012 – H1 2017 (USD Billion)
Table 20.33 KADCYLA®: Registered Clinical Trials
Table 20.34 KADCYLA® Sales: 2013- Q1 2017 (CHF Million)
Table 20.35 RG-7596: Registered Clinical Trials
Table 20.36 Sanofi: Revenues, 2012-2016 (USD Billion)
Table 20.37 SAR-566658: Registered Clinical Trials
Table 20.38 Seattle Genetics: Revenue 2012-H1 2017 (EUR Million)
Table 20.39 ADCETRIS®: Registered Clinical Trials
Table 20.40 ADCETRIS® Sales: 2012- H1 2017 (USD Million)
Table 20.41 SGN-CD19A: Registered Clinical Trials
Table 20.42 ADCs Partnerships Cumulative Trend, 2005-2017
Table 20.43 ADCs Partnerships: Key Players
Table 20.44 ADCs Partnerships: Distribution by Types
Table 20.45 ADCs Partnerships: Distribution by Year Wise Trend
Table 20.46 ADCs Investments: Cumulative Number of Funding Instances, Pre 2007 – 2017
Table 20.47 ADCs Investments: Cumulative Amount Invested, 2007- 2017 (USD Million)
Table 20.48 ADCs Investments: Distribution of Number of Funding Instance by Type, 2007 – 2017
Table 20.49 ADCs Investments: Distribution of Funding Amount by Funding Type, 2007 – 2017 (USD Million)
Table 20.50 ADCs Investments: Distribution by Leading Players
Table 20.51 ADCs Investments: Distribution by Leading Investors
Table 20.52 Academic Grant Analysis: Distribution of Number of Grants
Table 20.53 Academic Grant Analysis: Distribution by Grant Type
Table 20.54 Academic Grant Analysis: Distribution by Leading Organizations
Table 20.55 Academic Grant Analysis: Cumulative Distribution by Therapeutic Area
Table 20.56 Academic Grant Analysis: Distribution by Therapeutic Target
Table 20.57 ADCs Clinical Studies: Distribution by Type of Therapy Evaluation
Table 20.58 ADCs Combination Therapy Clinical Studies: Distribution by Highest Phase of Development
Table 20.59 ADCs Combination Therapy Clinical Studies: Distribution by Trial Status
Table 20.60 ADC Patents: Distribution by Type of Patent
Table 20.61 ADCs Patents: Distribution by Publication Year
Table 20.62 ADCs Patents: Year-wise Regional Distribution
Table 20.63 ADCs Patents: Distribution by Leading Assignees
Table 20.64 ADCs Patents: Benchmarking by Patent Characteristics
Table 20.65 ADCs Patents: Benchmarking by International Patents
Table 20.66 ADC Patents: Age of Patent
Table 20.67 ADCs Patents: Patent Valuation
Table 20.68 Overall ADCs Therapeutics Market, 2017-2030: Optimistic Scenario (USD Billion)
Table 20.69 Overall ADCs Therapeutics Market, 2017-2030: Base Scenario (USD Billion)
Table 20.70 Overall ADCs Therapeutics Market, 2017-2030: Conservative Scenario (USD Billion)
Table 20.71 Overall ADCs Therapeutics Market (USD Million), Base Scenario)
Table 20.72 ADCs Therapeutics Market (USD Billion), 2017 (Base Scenario): Distribution by Technology Providers
Table 20.73 ADCs Therapeutics Market (USD Billion), 2025 (Base Scenario): Distribution by Technology Providers
Table 20.74 ADCs Therapeutics Market (USD Billion), 2025 (Base Scenario): Distribution by Technology Providers
Table 20.75 ADCs Therapeutics Market (USD Billion), 2017 (Base Scenario): Distribution by Type of Linker
Table 20.76 ADCs Therapeutics Market (USD Billion), 2025 (Base Scenario): Distribution by Type of Linker
Table 20.77 ADCs Therapeutics Market (USD Billion), 2030 (Base Scenario): Distribution by Type of Linker
Table 20.78 ADCs Therapeutics Market (USD Billion), 2017 (Base Scenario): Distribution by Type of Payload
Table 20.79 ADCs Therapeutics Market (USD Billion), 2025 (Base Scenario): Distribution by Type of Payload
Table 20.80 ADCs Therapeutics Market (USD Billion), 2030 (Base Scenario): Distribution by Type of Payload
Table 20.81 ADCETRIS® Sales Forecast (Till 2030): Base Scenario (USD Million)
Table 20.82 ADCETRIS® Sales Forecast (Till 2030): Conservative Scenario (USD Million)
Table 20.83 ADCETRIS® Sales Forecast (Till 2030): Optimistic Scenario (USD Million)
Table 20.84 KADCYLA® Sales Forecast (Till 2030): Base Scenario (USD Million)
Table 20.85 KADCYLA® Sales Forecast (Till 2030): Conservative Scenario (USD Million)
Table 20.86 KADCYLA® Sales Forecast (Till 2030): Optimistic Scenario (USD Million)
Table 20.87 MYLOTARG™ Sales Forecast (Till 2030): Base Scenario (USD Million)
Table 20.88 MYLOTARG™ Sales Forecast (Till 2030): Conservative Scenario (USD Million)
Table 20.89 MYLOTARG™ Sales Forecast (Till 2030): Optimistic Scenario (USD Million)
Table 20.90 BESPONSA® Sales Forecast (Till 2030): Base Scenario (USD Million)
Table 20.91 BESPONSA® Sales Forecast (Till 2030): Conservative Scenario (USD Million)
Table 20.92 BESPONSA® Sales Forecast (Till 2030): Optimistic Scenario (USD Million)
Table 20.93 IMMU-132 Sales Forecast (Till 2030): Base Scenario (USD Million)
Table 20.94 IMMU-132 Sales Forecast (Till 2030): Conservative Scenario (USD Million)
Table 20.95 IMMU-132 Sales Forecast (Till 2030): Optimistic Scenario (USD Million)
Table 20.96 Rova-T Sales Forecast (Till 2030): Base Scenario (USD Million)
Table 20.97 Rova-T Sales Forecast (Till 2030): Conservative Scenario (USD Million)
Table 20.98 Rova-T Sales Forecast (Till 2030): Optimistic Scenario (USD Million)
Table 20.99 IMGN853 Sales Forecast (Till 2030): Base Scenario (USD Million)
Table 20.100 IMGN853 Sales Forecast (Till 2030): Conservative Scenario (USD Million)
Table 20.101 IMGN853 Sales Forecast (Till 2030): Optimistic Scenario (USD Million)
Table 20.102 RG7596 Sales Forecast (Till 2030): Base Scenario (USD Million)
Table 20.103 RG7596 Sales Forecast (Till 2030): Conservative Scenario (USD Million
Table 20.104 RG7596 Sales Forecast (Till 2030): Optimistic Scenario (USD Million
Table 20.105 PSMA ADC Sales Forecast (Till 2030): Optimistic Scenario (USD Million)
Table 20.106 PSMA ADC Sales Forecast (Till 2030): Base Scenario (USD Million)
Table 20.107 PSMA ADC Sales Forecast (Till 2030): Conservative Scenario (USD Million)
Table 20.108 BAY 94-9343 Sales Forecast (Till 2030): Optimistic Scenario (USD Million
Table 20.109 BAY 94-9343 Sales Forecast (Till 2030): Base Scenario (USD Million
Table 20.110 BAY 94-9343 Sales Forecast (Till 2030): Conservative Scenario (USD Million)
Table 20.110 SAR3419 Sales Forecast (Till 2030): Base Scenario (USD Million)
Table 20.111 SAR3419 Sales Forecast (Till 2030): Conservative Scenario (USD Million)
Table 20.112 SAR3419 Sales Forecast (Till 2030): Optimistic Scenario (USD Million)
Table 20.113 IMMU-130 Sales Forecast (Till 2030): Base Scenario (USD Million)
Table 20.114 IMMU-130 Sales Forecast (Till 2030): Conservative Scenario (USD Million)
Table 20.115 IMMU-130 Sales Forecast (Till 2030): Optimistic Scenario (USD Million)
Table 20.116 AGS 16M8F / AGS 16C3F Sales Forecast (Till 2030): Base Scenario (USD Million)
Table 20.117 AGS 16M8F / AGS 16C3F Sales Forecast (Till 2030): Conservative Scenario (USD Million)
Table 20.118 AGS 16M8F / AGS 16C3F Sales Forecast (Till 2030): Optimistic Scenario (USD Million)
Table 20.119 CDX-011 Sales Forecast (Till 2030): Base Scenario (USD Million)
Table 20.120 CDX-011 Sales Forecast (Till 2030): Conservative Scenario (USD Million)
Table 20.121 CDX-011 Sales Forecast (Till 2030): Optimistic Scenario (USD Million)
Table 20.122 SAR56668 Sales Forecast (Till 2030): Base Scenario (USD Million)
Table 20.123 SAR56668 Sales Forecast (Till 2030): Conservative Scenario (USD Million)
Table 20.124 SAR56668 Sales Forecast (Till 2030): Optimistic Scenario (USD Million)
Table 20.125 ABT-414 Sales Forecast (Till 2030): Base Scenario (USD Million)
Table 20.126 ABT-414 Sales Forecast (Till 2030): Conservative Scenario (USD Million)
Table 20.127 ABT-414 Sales Forecast (Till 2030): Optimistic Scenario (USD Million)
Table 20.128 SGN-CD19A Sales Forecast (Till 2030): Optimistic Scenario (USD Million)
Table 20.129 SGN-CD19A Sales Forecast (Till 2030): Base Scenario (USD Million)
Table 20.130 SGN-CD19A Sales Forecast (Till 2030): Conservative Scenario (USD Million)
Table 20.131 IMGN529 Sales Forecast (Till 2030): Base Scenario (USD Million)
Table 20.132 IMGN529 Sales Forecast (Till 2030): Conservative Scenario (USD Million)
Table 20.133 IMGN529 Sales Forecast (Till 2030): Optimistic Scenario (USD Million)
Table 20.134 ASG-22ME Sales Forecast (Till 2030): Base Scenario (USD Million)
Table 20.135 ASG-22ME Sales Forecast (Till 2030): Conservative Scenario (USD Million)
Table 20.136 ASG-22ME Sales Forecast (Till 2030): Optimistic Scenario (USD Million)
Table 20.137 Overall ADCs Therapeutic Market: Conservative, Base and Optimistic Scenario, 2017, 2025 and 2030 (USD Billion)
The following companies and organizations have been mentioned in the report:
PRICING DETAILS
Discounts available for multiple report purchases
sales@rootsanalysis.com
SUBSCRIBE TO INDUSTRY UPDATES